ClinicalTrials.gg
RecruitingNCT05479006Updated Oct 23, 2026

Determine the Effect of Targeted High-definition Transcranial Direct Current Stimulation (tDCS) on Reducing Post-stroke Upper Limb Motor Impairments

An interventional study of Transcranial direct current stimulation (high- definition) in Stroke, sponsored by Carle Foundation Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Carle Foundation Hospital · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.

Planned enrollment
912th of 1,621
30 · median 40
Started
2022
with 101 others
No phase
1,124 of 1,995
270 open now
Primary completion
2027-01
later than 175 of 488 live
Registered
1,522nd of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 912th largest by planned enrollment of the 1,621 interventional ones that give a count, is one of 102 that started in 2022, is one of 1,124 with no phase, reaches primary completion later than 175 of the 488 other live ones, and was the 1,522nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

387 more — sign in →

All 392 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

Significant motor impairments occur in 80% of individuals after moderate to severe stroke and impact the body side to the lesioned hemisphere. Typical motor impairments involve loss of dexterity with highly prevalent upper limb flexion synergy. Advances in treating flexion synergy impairments have been hampered by a lack of precision rehabilitation. Previous studies suggest and support the role of cortico-reticulospinal tract (CRST) hyperexcitability in post-stroke flexion synergy. CRST hyperexcitability is often caused by damage to the corticospinal tract (CST). We hypothesize that: 1) inhibiting the contralesional dorsal premotor cortex (cPMd) will directly reduce the CRST hyperexcitability and thus, reduce the expression of the flexion synergy; 2) facilitating the ipsilesional primary motor cortex (iM1) will improve the excitability of the damaged CST, therefore reducing the CRST hyperexcitability and the flexion synergy. we propose to use a novel targeted high-definition tDCS (THD-tDCS) to specifically modulate the targeted cortical regions for testing his hypothesis, via the following aims: Aim 1. Evaluate the effect of cathodal THD-tDCS over the cPMd on reducing the CRST hyperexcitability and the expression of flexion synergy. Aim 2. Evaluate the effect of anodal THD-tDCS over the iM1 on improving the excitability of the CST, and determine whether this, thus, also reduces the CRST hyperexcitability and the flexion synergy. Aim 3. Evaluate the confluence effect of bilateral THD-tDCS, i.e., simultaneous cathodal stimulation over the cPMd and anodal over the iM1.

Read the detailed description

This sham-controlled cross-over study design will include four visits: 1) anodal stimulation targeting the ipsilesional hemisphere, 2) cathodal one at the contralesional hemisphere, 3) bilateral stimulation with anodal on the ipsilesional hemisphere and cathodal on the contralesional hemisphere and 4) a sham stimulation visit. The sequence of the stimulations will be randomized and double-blinded (assessor and participants). After each intervention, there will be at least 2 weeks wash-out period before participants receive the next intervention and assessments. Each visit will last up to 3 hours including the preparation time and breaks.

We will use neuro-navigation high-definition tDCS (NNG HD-tDCS) to target specific brain regions in a more precise way than before. A subject-specific head model will be built to evaluate the effect of lesion size and location on the electrical field of tDCS. The MR images (if available, otherwise CT images) will be used to build this subject-specific head model. The stimulation electrode montage and inter-electrode distance will be carefully examined by computer simulation to determine the optimal setup and dosage for NNG HD-tDCS.

The patient time commitment in this study is approximately 10 weeks where subjects have 4 x 1-day intervention and measurements, with 2 weeks washout the period in between.

The total number of potential enrolled subjects in this pilot study is 30.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • Non-invasive Brain Stimulation
  • Movement Impairment
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Paresis confined to one side, with substantial motor impairment of the paretic upper limb
  • Capacity to provide

Exclusion criteria

Exclusion Criteria:

  • Muscle tone abnormalities and motor or sensory impairment in the non-paretic limb
  • Severe wasting or contracture or significant sensory deficits in the paretic upper limb
  • Severe cognitive or affective dysfunction that prevents normal communication and understanding of consent or instruction
  • Severe concurrent medical problems (e.g. cardiorespiratory impairment)
  • Using a pacemaker
  • Metal implants in the head
  • Known adverse reactions to TMS and tDCS
  • Pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Anodal stimulation

    Anodal stimulation targets the primary motor cortex (arm area) in the lesioned hemisphere, sham on the contralesional hemisphere.

    Device: Transcranial direct current stimulation (high- definition)

  • Active comparator
    Cathodal stimulation

    Cathodal stimulation targets the dorsal premotor cortex (arm area) in the contralesional hemisphere, sham on the lesioned hemisphere.

    Device: Transcranial direct current stimulation (high- definition)

  • Active comparator
    Bilateral Stimulation

    Anodal stimulation targets the primary motor cortex (arm area) in the lesioned hemisphere and cathodal stimulation targets the dorsal premotor cortex (arm area) in the contralesional hemisphere at the same time.

    Device: Transcranial direct current stimulation (high- definition)

  • Sham comparator
    Sham stimulation

    Sham stimulation to both hemisphere of the brain

    Device: Transcranial direct current stimulation (high- definition)

Interventions

  • DeviceTranscranial direct current stimulation (high- definition)

    20 minutes, 2 mA stimulation.

06

What researchers measure

Primary outcomes

  1. Change in Transcranial Magnetic Stimulation-Evoke Motor-evoked Potential 1: Ispilesional stimulation in the brain and contralateral response in the muscle

    This is a neurophysiological measure that determines the use of the ipsilesional corticospinal tract.

    Time frame: Baseline (initial visit), before (within 30 min range) and immediately after (within 30 min range) the intervention

  2. Change in Transcranial Magnetic Stimulation-Evoke Motor-evoked Potential 2: Contralesional stimulation in the brain and ipsilateral response in the muscle

    This is a neurophysiological measure that determines the use of the contralesional cortico-reticulospinal tract.

    Time frame: Baseline (initial visit), before (within 30 minutes range) and immediately after (within 30 minutes range) the intervention

Secondary outcomes

  1. Change in a subset of Fugl-Meyer Upper Extremity assessment which is mainly related to the muscle synergies

    This clinical measure is mainly related to the upper limb muscle synergies

    Time frame: Baseline (initial visit), before (within 30 minutes range) and immediately after (within 30 minutes range) the intervention

  2. Change in Fugl-Meyer Upper Extremity assessment

    This reflects the overall motor impairment level.

    Time frame: Baseline (initial visit), before (within 30 minutes range) and immediately after (within 30 minutes range) the intervention

Other outcomes

  1. Modified Ashworth Scale

    This indicates the expression of muscle tone or spasticity

    Time frame: Baseline (initial visit), before (within 30 minutes range) and immediately after (within 30 minutes range) the intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Williamson JN, James SA, Mulyana B, Kim S, He D, Li S, Sidorov EV, Yang Y. Quantitative EEG Metrics for Determining HD-tDCS Induced Alteration of Brain Activity in Stroke Rehabilitation. Restor Neurol Neurosci. 2024 Nov;42(3-4):209-221. doi: 10.1177/09226028251347427. Epub 2025 Jun 16. PubMed 40518976 ↗
  • Yang, Y., Sidorov, E., & Dewald, J. P. (2021). Targeted tDCS reduces the expression of the upper limb flexion synergy in chronic hemiparetic stroke. Archives of Physical Medicine and Rehabilitation, 102(10), e10.
  • Peng RH, He D, James SA, Williamson JN, Skadden C, Jain S, Hassaneen W, Miranpuri A, Kaur A, Sarol JN, Yang Y. Determining the effects of targeted high-definition transcranial direct current stimulation on reducing post-stroke upper limb motor impairments-a randomized cross-over study. Trials. 2024 Jan 9;25(1):34. doi: 10.1186/s13063-023-07886-w. PubMed 38195605 ↗
  • Williamson JN, James SA, He D, Li S, Sidorov EV, Yang Y. High-definition transcranial direct current stimulation for upper extremity rehabilitation in moderate-to-severe ischemic stroke: a pilot study. Front Hum Neurosci. 2023 Oct 12;17:1286238. doi: 10.3389/fnhum.2023.1286238. eCollection 2023. PubMed 37900725 ↗

Individual participant data

Plan to share: No — We are committed to enhancing the value of research and furthering the advancement of public knowledge. We recognize that the public dissemination of our scientific results can facilitate the creation of collaborative efforts with domestic and international collaborators. Furthermore, we recognize that the proposed project may result in novel ideas for new methods, technologies, and data that could benefit the entire research community. Therefore, final research data will be shared openly and timely in accordance with the most recent NIH guidelines (http://grants.nih.gov/grants/policy/data_sharing/) while being mindful that the confidentiality and privacy of participants in research must be protected at all times.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Jan 2027, 52 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 52 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jun 2026 → Jan 2027 and completion Jun 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Jul 28, 2022
StartActual
Sep 30, 2022
Primary completionEst.
Jan 30, 2027was Jun 2026
CompletionEst.
Mar 1, 2027was Jun 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Jan 30, 2027
Oct 23, 2026
Study completion
Jun 30, 2026→Mar 1, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Jun 30, 2026→Jan 30, 2027
    Study completion Jun 30, 2026→Mar 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05479006
Lead sponsor
Carle Foundation Hospital
Collaborators
American Heart Association
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Sep 30, 2022
Primary completion
Jan 30, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Yuan Yang, PhD
Contact
yuan.yang@carle.com
217-244-5870
Sanjiv Jain, MD
Contact
sanjiv.jain@carle.com
217-383-3800

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion